Company news

CG Oncology, Inc. news in 2025

CG Oncology, Inc.'s news releases, calls and decks from 2025, newest first.

View company

SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

December 17, 2025

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

December 4, 2025

CG Oncology Announces New Board Member and Board Transition

November 25, 2025

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 13, 2025

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

September 4, 2025

CG Oncology Completes Enrollment in PIVOT-006

September 2, 2025

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

August 28, 2025

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

July 28, 2025

Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors

July 1, 2025

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 12, 2025

SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

April 30, 2025

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

April 25, 2025

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

April 23, 2025

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

March 30, 2025

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

March 27, 2025

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

March 23, 2025

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

March 11, 2025

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

February 25, 2025

Decks in 2025